Technical Analysis for REDX - Redx Pharma Plc
| ADX | Long Term | Intermediate Term | Short Term |
|---|---|---|---|
| Strong | Down | Down | Up |
| Date | Alert Name | Type | % Chg |
|---|---|---|---|
| Crossed Above 20 DMA | Bullish | 31.58% | |
| Multiple of Ten Bullish | Other | 31.58% | |
| Wide Bands | Range Expansion | 31.58% | |
| Fell Below 20 DMA | Bearish | 66.67% | |
| Doji - Bullish? | Reversal | 66.67% | |
| Wide Bands | Range Expansion | 66.67% | |
| Gapped Down | Weakness | 66.67% | |
| Crossed Above 20 DMA | Bullish | 50.00% | |
| Wide Bands | Range Expansion | 50.00% | |
| NR7 | Range Contraction | 62.16% |
| Alert | Time |
|---|---|
| 50 DMA Resistance | 4 minutes ago |
| Up 2 ATRs | about 3 hours ago |
| Up 1 ATR | about 3 hours ago |
| Up 10% | about 3 hours ago |
| 10 DMA Support | about 3 hours ago |
Get a Trading Assistant
Redx Pharma Plc Description
Redx Pharma Plc, formerly Redx Pharma Ltd, is engaged in drug discovery, pre-clinical development and licensing. The Company is engaged in drug discovery across cancer, infection and autoimmune diseases. The Company has over two programs in its oncology research activity, Smoothened Hedgehog (SMO) and Bruton's Tyrosine Kinase (BTK), which has reached candidate nomination stage. The Company's oncology research activity also include Porcupine program, Colony Stimulating Factor-1 receptor (CSF-1) program, Indoleamine-pyrrole 2,3-dioxygenase (IDO) inhibitor and Pan-Raf inhibitor. The Company's anti-infective candidate compound is an antibiotic that the Company has developed to treat a range of Gram-positive bacterial infections, including resistant strains, such as Methicillin-Resistant Staphylococcus Aureus (MRSA). Its product candidate, RDX003, is a class of antibiotic acting through the type II bacterial topoisomerases. It is also evaluating BTK inhibitor for immunological disorders.
Classification
Sector: Healthcare
Industry: Biotechnology
Keywords: Hedge Cancer Disease Branches Of Biology Medical Specialties Clinic Diseases Oncology Mr Drug Discovery Infection Infectious Diseases Autoimmune Diseases Antibiotic Disorders Oxygen Infections Bacteria Bacterial Diseases Erase Healthcare Associated Infections Kinase Methicillin Staphylococcus Aureus Tyrosine Kinase
| Indicator | Bull Case | Neutral / Hold | Bear Case |
|---|---|---|---|
| 50 DMA | |||
| 200 DMA | |||
| ADX Trend | |||
| Oversold / Overbought | |||
| Relative Strength |
| Indicator | Value |
|---|---|
| 52 Week High | 37.9 |
| 52 Week Low | 4.0 |
| Average Volume | 843,642 |
| 200-Day Moving Average | 21.89 |
| 50-Day Moving Average | 15.24 |
| 20-Day Moving Average | 9.02 |
| 10-Day Moving Average | 11.14 |
| Average True Range | 2.09 |
| RSI (14) | 48.19 |
| ADX | 25.9 |
| +DI | 24.02 |
| -DI | 26.79 |
| Chandelier Exit (Long, 3 ATRs) | 13.14 |
| Chandelier Exit (Short, 3 ATRs) | 10.28 |
| Upper Bollinger Bands | 14.06 |
| Lower Bollinger Band | 3.98 |
| Percent B (%b) | 0.74 |
| BandWidth | 111.75 |
| MACD Line | -1.33 |
| MACD Signal Line | -1.77 |
| MACD Histogram | 0.4338 |
| Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
|---|---|---|---|---|---|
| Resistance 4 (R4) | 17.03 | ||||
| Resistance 3 (R3) | 16.52 | 14.13 | 16.09 | ||
| Resistance 2 (R2) | 14.13 | 12.70 | 14.39 | 15.77 | |
| Resistance 1 (R1) | 12.77 | 11.82 | 13.45 | 13.28 | 15.46 |
| Pivot Point | 10.38 | 10.38 | 10.73 | 10.64 | 10.38 |
| Support 1 (S1) | 9.02 | 8.95 | 9.70 | 9.53 | 7.34 |
| Support 2 (S2) | 6.63 | 8.07 | 6.89 | 7.03 | |
| Support 3 (S3) | 5.27 | 6.63 | 6.71 | ||
| Support 4 (S4) | 5.78 |
